The long-term goal of the Genomics of Acute Myeloid Leukemia Program Project Grant (GAML PPG) is to define all of the genetic events that contribute to the pathogenesis of AML, and to use this information to improve the risk assessment and treatment of patients with this disease. This goal will be addressed in a highly integrated and productive PPG structure that involves four projects and four cores. During the past 5 years, the members of this PPG developed the approaches (that are now widely used) to perform whole genome sequencing of AML genomes, and to validate all variants with custom capture arrays and deep digital sequencing. We have contributed 200 AML samples to The Cancer Genome Atlas for their AML project, which is led by two of our PPG members (Ley and Wilson). Although analysis of this enormous dataset is ongoing, these studies have led to the discovery of more than 200 recurrently mutated genes in AML, including DNMT3A, U2AF1, and IDH1, representing new classes of mutations that were not previously (

Public Health Relevance

Acute myeloid leukemia is a heterogeneous group of malignancies of blood forming cells that are associated with a high rate of relapse and death, even with state-of-the-art therapy. The genetic basis of the disease must be solved so that risk assessment can be improved, and novel therapeutic approaches can be developed. We are sequencing the genomes and transcriptomes of AML cases to define the genetic factors that contribute to drug resistance and early relapse, which may provide new approaches for therapy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (J1))
Program Officer
Li, Jerry
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Internal Medicine/Medicine
Schools of Medicine
Saint Louis
United States
Zip Code
Engle, E K; Fisher, D A C; Miller, C A et al. (2015) Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia. Leukemia 29:869-76
Al-Hussaini, Muneera; DiPersio, John F (2014) Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic. Expert Rev Hematol 7:439-64
Jacoby, M A; De Jesus Pizarro, R E; Shao, J et al. (2014) The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia. Leukemia 28:1242-51
Sarkaria, S M; Christopher, M J; Klco, J M et al. (2014) Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro. Leukemia 28:2403-6
Miller, Christopher A; White, Brian S; Dees, Nathan D et al. (2014) SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol 10:e1003665
Klco, Jeffery M; Spencer, David H; Miller, Christopher A et al. (2014) Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 25:379-92
Russler-Germain, David A; Spencer, David H; Young, Margaret A et al. (2014) The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25:442-54
Hughes, Andrew E O; Magrini, Vincent; Demeter, Ryan et al. (2014) Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet 10:e1004462
White, Brian S; DiPersio, John F (2014) Genomic tools in acute myeloid leukemia: From the bench to the bedside. Cancer 120:1134-44
Grieselhuber, N R; Klco, J M; Verdoni, A M et al. (2013) Notch signaling in acute promyelocytic leukemia. Leukemia 27:1548-57

Showing the most recent 10 out of 65 publications